Bone marrow-derived cell mobilization promotes the progression of atherosclerosis and tissue regeneration

动脉粥样硬化是慢性炎症性疾病之一，在西方国家是心脏病或中风的主要病因。我们研究了环磷酰胺（CPA），一种众所周知的免疫调节剂和抗癌药物，在小鼠动脉粥样硬化模型中的作用。持续口服CPA可抑制载脂蛋白E缺乏患者的疾病发生。持续给药CPA可阻止巨噬细胞流入已形成的动脉粥样硬化斑块。在这里，动脉粥样硬化的进展没有显著差异，尽管与载体处理的小鼠相比，在cpa处理的小鼠中观察到斑块形成较少的趋势。化疗调节体内淋巴细胞群如TH1/ TH2平衡。此外，脉冲CPA治疗通过降低基质金属蛋白酶-2和-9的表达来改善斑块的稳定性。我们的数据表明，化疗有可能作为晚期动脉粥样硬化的可选治疗方法。

Atherosclerosis is one of the chronic inflammatory diseases, and the primary cause of heart disease or stroke in western countries. We investigated the effects of cyclophosphamide (CPA), a well-known immunomodulator and anticancer drug, in a murine model of established atherosclerosis. Continuous oral administration of CPA inhibited disease initiation in apolipoprotein E deficient, fed a high fat diet. Continuous CPA administration prevented from macrophage influx into formed atherosclerotic plaques. Here, atheroma progression was not significantly different even though a trend towards less plaque formation was observed in CPA-treated as compared to carrier-treated mice. Chemotherapy regulates lymphoid population like TH1/ TH2 balance in vivo. Additionally, pulse CPA treatment improved plaque stability with the decrease of matrixmetalloproteinase-2 and -9 expression. Our data suggest chemotherapy has a possibility as an optional therapy for advanced atherosclerosis.